JP2022550174A5 - - Google Patents

Info

Publication number
JP2022550174A5
JP2022550174A5 JP2022519804A JP2022519804A JP2022550174A5 JP 2022550174 A5 JP2022550174 A5 JP 2022550174A5 JP 2022519804 A JP2022519804 A JP 2022519804A JP 2022519804 A JP2022519804 A JP 2022519804A JP 2022550174 A5 JP2022550174 A5 JP 2022550174A5
Authority
JP
Japan
Prior art keywords
therapeutic
compound
diagnostic
dextran
skeleton
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022519804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550174A (ja
JP7599727B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/053604 external-priority patent/WO2021067479A1/en
Publication of JP2022550174A publication Critical patent/JP2022550174A/ja
Publication of JP2022550174A5 publication Critical patent/JP2022550174A5/ja
Application granted granted Critical
Publication of JP7599727B2 publication Critical patent/JP7599727B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022519804A 2019-09-30 2020-09-30 マンノシル化デキストラン治療用または診断用化合物の標的特異性を高めるためのキット Active JP7599727B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962908136P 2019-09-30 2019-09-30
US62/908,136 2019-09-30
PCT/US2020/053604 WO2021067479A1 (en) 2019-09-30 2020-09-30 Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands

Publications (3)

Publication Number Publication Date
JP2022550174A JP2022550174A (ja) 2022-11-30
JP2022550174A5 true JP2022550174A5 (cg-RX-API-DMAC10.html) 2023-09-28
JP7599727B2 JP7599727B2 (ja) 2024-12-16

Family

ID=75337533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022519804A Active JP7599727B2 (ja) 2019-09-30 2020-09-30 マンノシル化デキストラン治療用または診断用化合物の標的特異性を高めるためのキット

Country Status (7)

Country Link
US (1) US20210145989A1 (cg-RX-API-DMAC10.html)
EP (1) EP4021459A4 (cg-RX-API-DMAC10.html)
JP (1) JP7599727B2 (cg-RX-API-DMAC10.html)
CN (1) CN115151264B (cg-RX-API-DMAC10.html)
CA (1) CA3155675A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022003699A (cg-RX-API-DMAC10.html)
WO (1) WO2021067479A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3192041A1 (en) * 2020-08-21 2022-02-24 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
EP4472643A1 (en) * 2022-02-04 2024-12-11 Navidea Biopharmaceuticals, Inc. Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
US20230302041A1 (en) * 2022-03-25 2023-09-28 Navidea Biopharmaceuticals, Inc. Competitive Self-Blocking with Unlabeled Manocept Imaging Agents
CN114894698B (zh) * 2022-04-15 2023-02-03 广东省第二人民医院(广东省卫生应急医院) MDSCs在再生障碍性贫血诊断和/或分型中的应用
US20240024491A1 (en) * 2022-07-13 2024-01-25 Navidea Biopharmaceuticals, Inc. Mannosylated amine dextran drug delivery vehicles with degradable disulfide/carbonate linkers targeting payloads to cd206 expressing cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624046A (en) * 1982-01-04 1986-11-25 Fairchild Camera & Instrument Corp. Oxide isolation process for standard RAM/PROM and lateral PNP cell RAM
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
JP3582234B2 (ja) * 1996-05-20 2004-10-27 ニプロ株式会社 IgA腎症特異的フィブロネクチン断片、その検出方法およびキット
US6409990B1 (en) * 1999-05-14 2002-06-25 The Regents Of The University Of California Macromolecular carrier for drug and diagnostic agent delivery
EP1501522A4 (en) * 2002-05-06 2007-12-05 Univ Utah Res Found PRE-BLOCKING WITH NON-HA GAGS INCREASES THE EFFECTIVENESS OF HA-CONJUGATED CANCER
US20050169883A1 (en) * 2002-05-06 2005-08-04 Prestwich Glenn D. Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
WO2005086639A2 (en) * 2004-02-10 2005-09-22 Barnes-Jewish Hospital Improved efficacy and safety of targeted particulate agents with decoy systems
JP4543860B2 (ja) * 2004-09-30 2010-09-15 株式会社島津製作所 試料の解析方法
US20080182816A1 (en) * 2006-02-23 2008-07-31 Tam Joemy C Methods for preparing a novel family of polysaccharride prodrugs for colonic delivery
US20140235790A1 (en) * 2011-06-10 2014-08-21 University Of Washington Through Its Center For Commercialization Carbohydrate-based compositions and methods for targeted drug delivery
HK1225623A1 (zh) * 2013-07-22 2017-09-15 纳维迪亚生物制药有限公司 用於诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒
WO2016011419A1 (en) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis
CA2955438C (en) * 2014-07-17 2024-07-02 Ohio State Innovation Foundation DEXTRANE CONJUGATES TO TARGET MACROPHAGES AND OTHER CELLS EXPRESSING THE D-MANBOSE BINDING TYPE C LECTIN RECEPTOR
CA2974634A1 (en) * 2015-01-21 2016-07-28 Navidea Biopharmaceuticals, Inc. Compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells
WO2018068060A1 (en) * 2016-10-07 2018-04-12 Navidea Biopharmaceuticals, Inc. Compounds and methods for diagnosis and treatment of viral infections
US20190021608A1 (en) * 2017-05-19 2019-01-24 Navidea Biopharmaceuticals, Inc. CD206+ Macrophage-Specific Molecular Imaging Probe Compositions and Methods and the Noninvasive Quantification of Arterial Wall Macrophage Infiltration in Humans
WO2019018815A1 (en) * 2017-07-21 2019-01-24 Navidea Biopharmaceuticals, Inc. USE OF 99MTC-TILMANOCEPT AND ASSOCIATED MOLECULAR CONSTRUCTS FOR THE IDENTIFICATION AND DIAGNOSIS OF MALIGNANT TUMORS, AND FOR THE MONITORING OF ANTI-TUMOR THERAPEUTIC INTERVENTIONS

Similar Documents

Publication Publication Date Title
JP4056701B2 (ja) 薬剤および診断薬の送達のための高分子担体
JP2025061126A (ja) Ror1抗体イムノコンジュゲートによる癌の治療
JP2025137626A5 (cg-RX-API-DMAC10.html)
JP2021501754A5 (cg-RX-API-DMAC10.html)
CN1635910A (zh) 巨噬细胞介导的疾病的治疗和诊断
JP2020007350A5 (cg-RX-API-DMAC10.html)
JP2005511533A (ja) 標的デリバリ用デントリマ
JP2006513992A5 (cg-RX-API-DMAC10.html)
JP2001515708A5 (cg-RX-API-DMAC10.html)
JP2006316040A5 (cg-RX-API-DMAC10.html)
JP2018168165A5 (cg-RX-API-DMAC10.html)
JP2011528710A5 (cg-RX-API-DMAC10.html)
JP2025165975A5 (cg-RX-API-DMAC10.html)
JP2021514003A5 (cg-RX-API-DMAC10.html)
JP2023542295A5 (cg-RX-API-DMAC10.html)
JP2022537019A5 (cg-RX-API-DMAC10.html)
JP2024510267A5 (cg-RX-API-DMAC10.html)
ES2599032T3 (es) Método de tratamiento y bioensayo que implica el factor de inhibición de la migración de macrófagos (MIF) como factor depresor del miocardio de origen cardiaco
JP2025501978A5 (cg-RX-API-DMAC10.html)
JP2023503769A5 (cg-RX-API-DMAC10.html)
JP2023510865A5 (cg-RX-API-DMAC10.html)
Lindén et al. A Novel Platform for Radioimmunotherapy: Extracorporeal Depletion of Biotinylated and90Y-Labeled Rituximab in Patients with Refractory B-Cell Lymphoma
Koyama et al. Effect of chemical cationization of antigen on glomerular localization of immune complexes in active models of serum sickness nephritis in rabbits
JP2025508328A5 (cg-RX-API-DMAC10.html)
JPWO2025047983A5 (cg-RX-API-DMAC10.html)